One Cell paper put a peptide on the map in 2017 that selectively drives aged cells into apoptosis. Nine years on, the structural basis has been resolved. Clinical validation still has not arrived. What exists, what is missing, and where the field is heading.
MVMichel van der VeenRegistered Nurse · Science Editor, Peptalis Sources checked via PubMed · 5 referencesReviewed September 2026 · 8 MIN READAgeing tissues accumulate a peculiar cell type: senescent cells. They no longer divide, yet they do not die either.
Cells that stop dividing but refuse to leave
They linger, secreting a mix of inflammatory factors that affects surrounding tissue. The research hypothesis that follows is as simple as it is ambitious: if these cells could be cleared selectively, part of age-related tissue damage might track with them. Agents attempting this are called senolytics, and one of them is a peptide.
What FOXO4-DRI is
Senescent cells survive partly because the protein FOXO4 holds on to p53, muting the cell's built-in self-destruct programme. FOXO4-DRI was designed to break precisely that handshake. It is a FOXO4 fragment rebuilt from D-amino acids in reversed order (a “D-retro-inverso” peptide, a design trick that preserves the spatial shape while slowing enzymatic breakdown), fused to a strongly cationic tail that carries it into cells. In the original work by Baar and colleagues (Cell, 2017), administration in mouse models of accelerated and natural ageing produced selective apoptosis of senescent cells, with restoration of fur density, running endurance and renal function markers.
What has been added since 2017, and what stands out
The structural basis has now been resolved: Bourgeois and colleagues (Nature Communications, 2025) solved NMR structural models of the complex and showed that FOXO4-DRI engages the disordered transactivation domain of p53, with the cell-penetrating tail itself contributing to binding. Preclinically, the track broadened: to senescent keloid fibroblasts (Communications Biology, 2025), to aged endothelial cells and vascular function in mice (Frontiers in Bioengineering and Biotechnology, 2026), and earlier to chondrocytes and Leydig cells. What stands out is what has not been added: independent replication of the original ageing results at comparable scale, and human data of any kind. A 2026 review in Antioxidants states it plainly: FOXO4-DRI shows senolytic activity in preclinical models but has not been clinically validated.
Where the research is heading
The open questions can be named concretely. First, replication: the 2017 core results deserve confirmation by groups without ties to the original work. Second, selectivity: p53 is the most closely guarded tumour suppressor in the cell, and an agent touching p53 signalling calls for systematic characterisation of its effects in healthy dividing cells. Third, delivery: which tissues does a peptide of this size actually reach, and for how long? For laboratories working on protein–protein interactions, peptide stability or senescence markers, this is a field where mechanistic work carries immediate weight: the literature is small enough that a single well-designed study visibly shifts the state of knowledge.
About the authorMVMichel van der VeenRegistered Nurse · Science Editor, PeptalisRegistered nurse with eleven years in psychiatry and founder of Peptalis. Writes the platform's knowledge layer: compound profiles, evidence reviews and the quality methodology. Works from primary literature (PubChem for chemistry, PubMed for studies) and states where evidence is absent.
Sources checked via PubMed · 5 references
Compound profilesEvidence reviewsQualityIN THIS ARTICLE- Cells that stop dividing but refuse to leave
- What FOXO4-DRI is
- What has been added since 2017, and what stands out
- Where the research is heading
Compounds in this article
- FOXO4-DRI · Not in catalogue · Research profile
For laboratory research use only. Not for human use.
SCIENTIFIC REFERENCES
These references are provided for informational and research purposes only. They do not constitute medical advice.
- 01Animal modelTargeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017;169(1):132-147.e16.doi 10.1016/j.cell.2017.02.031View on PubMed →
- 02In vitro / structuralThe disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI.Bourgeois B, et al. Nat Commun. 2025.doi 10.1038/s41467-025-60844-9View on PubMed →
- 03In vitroFOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation.Kong Y-X, et al. Commun Biol. 2025.doi 10.1038/s42003-025-07738-0View on PubMed →
- 04Animal modelFOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway.Hu Z, et al. Front Bioeng Biotechnol. 2026.doi 10.3389/fbioe.2025.1729166View on PubMed →
- 05ReviewFOXO4 as a Redox-Sensitive Regulator of Antioxidant Defense and Cellular Senescence.Mateescu D-M, et al. Antioxidants. 2026.doi 10.3390/antiox15070842View on PubMed →